Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity

Journal of Controlled Release

Volumn 115, Issue 1, 2006, Pages 57-67

  Lamalle Bernard, Delphine ^a   Munier, Séverine ^a   Compagnon, Christelle ^a   Charles, Marie Hélène ^a   Kalyanaraman, Vaniambadi S ^b   Delair, Thierry ^a   Verrier, Bernard ^a   Ataman Önal, Yasemin ^a  

^a BIOMÉRIEUX   (France)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

Author keywords

Antigenicity; Coadsorption; HIV 1 p24 and gp120 proteins; Immunogenicity; Surfactant free PLA nanoparticles; Vaccine adjuvant

Indexed keywords

ANTIGENS; BIODEGRADATION; IMMUNOLOGY; MOLECULAR STRUCTURE; PROTEINS; VACCINES;

COADSORPTION; HIV-1 P24/ GP120 PROTEINS; SURFACTANT FREE PLA NANOPARTICLES; VACCINE ADJUVANT;

NANOSTRUCTURED MATERIALS;

GAG PROTEIN; GLYCOPROTEIN GP 120; NANOPARTICLE; POLYLACTIC ACID;

ADSORPTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOGENICITY; IMMUNOSTIMULATION; ISOTHERM; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADSORPTION; AIDS VACCINES; ANIMALS; ANIONS; ANTIBODY SPECIFICITY; BINDING, COMPETITIVE; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; ESCHERICHIA COLI; FEMALE; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; IMMUNIZATION; LACTIC ACID; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; NANOSTRUCTURES; PARTICLE SIZE; POLYGLYCOLIC ACID; POLYMERS; RECOMBINANT PROTEINS; THERMODYNAMICS;

EID: 33748927941     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2006.07.006     Document Type: Article

References (30)

1. Jiang W., Gupta R.K., Deshpande M.C., and Schwendeman S.P. Biodegradable poly(lactic-co-glycolic acid) microparticles for injectable delivery of vaccine antigens. Adv. Drug Deliv. Rev. 57 (2005) 391-410
2. Singh M., Kazzaz J., Ugozzoli M., Malyala P., Chesko J., and O'Hagan D.T. Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr. Drug Deliv. 3 (2006) 115-120
3. Kazzaz J., Neidleman J., Singh M., Ott G., and O'Hagan D.T. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J. Control. Release 67 (2000) 347-356
4. Jung T., Kamm W., Breitenbach A., Hungerer K.D., Hundt E., and Kissel T. Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm. Res. 18 (2001) 352-360
5. Cui Z., Patel J., Tuzova M., Ray P., Phillips R., Woodward J.G., and Nath A. R.J. Mumper, Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles. Vaccine 22 (2004) 2631-2640
6. Ataman-Onal Y., Munier S., Ganée A., Terrat C., Durand P.Y., Battail N., Martinon F., Le Grand R., Charles M.H., Delair T., and Verrier B. Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J. Control. Release 112 (2006) 175-185
7. Aristegui J., Usonis V., Coovadia H., Riedemann S., Win K.M., Gatchalian S., and Bock H.L. Facilitating the WHO expanded program of immunization: the clinical profile of a combined diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b vaccine. Int. J. Infect. Dis. 7 (2003) 143-151
8. Tichmann I., Preidel H., Grunert D., Habash S., Schult R., Maier R., Gildberg P.K., Sengespeik H.C., Meurice F., and Sanger R. Comparison of the immunogenicity and reactogenicity of two commercially available hexavalent vaccines administered as a primary vaccination course at 2, 4 and 6 months of age. Vaccine 23 (2005) 3272-3279
9. Singh M., Li X.M., Wang H., McGee J.P., Zamb T., Koff W., Wang C.Y., and O'Hagan D.T. Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infect. Immun. 65 (1997) 1716-1721
10. Boehm G., Peyre M., Sesardic D., Huskisson R.J., Mawas F., Douglas A., Xing D., Merkle H.P., Gander B., and Johansen P. On technological and immunological benefits of multivalent single-injection microsphere vaccines. Pharm. Res. 19 (2002) 1330-1336
11. Peyre M., Audran R., Estevez F., Corradin G., Gander B., Sesardic D., and Johansen P. Childhood and malaria vaccines combined in biodegradable microspheres produce immunity with synergistic interactions. J. Control. Release 99 (2004) 345-355
12. H. Fessi, J.-P. Devissaguet, F. Puisieux, C. Thies. Process for the preparation of dispersible colloidal systems of a substance in the form nanoparticles. US Patent 5,118,528, European Patent EP0275796B2, December 31, 1986.
13. Janvier B., Archinard P., Mandrand B., Goudeau A., and Barin F. Linear B-cell epitopes of the major core protein of human immunodeficiency virus types 1 and 2. J. Virol. 64 (1990) 4258-4263
14. Allard L., Cheynet V., Oriol G., Gervasi G., Imbert-Laurenceau E., Mandrand B., Delair T., and Mallet F. Antigenicity of recombinant proteins after regioselective immobilization onto polyanhydride-based copolymers. Bioconjug. Chem. 15 (2004) 458-466
15. Burton D.R., Pyati J., Koduri R., Sharp S.J., Thornton G.B., Parren P.W., Sawyer L.S., Hendry R.M., Dunlop N., Nara P.L., Lamacchia M., Garratty E., Steihm E.R., Bryson Y.J., Cao Y., Moore J.P., Ho D.D., and Barbas C.F.I. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266 (1994) 1024-1027
16. Trkola A., Purtscher M., Muster T., Ballaun C., Buchacher A., Sullivan N., Srinivasan K., Sodroski J., Moore J.P., and Katinger H. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70 (1996) 1100-1108
17. Thali M., Moore J.P., Furman C., Charles M., Ho D.D., Robinson J., and Sodroski J. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J. Virol. 67 (1993) 3978-3988
18. Cavacini L., Duval M., Song L., Sangster R., Xiang S.H., Sodroski J., and Posner M. Conformational changes in env oligomer induced by an antibody dependent on the V3 loop base. AIDS 17 (2003) 685-689
19. Chesko J., Kazzaz J., Ugozzoli M., O'Hagan T., and Singh M. An investigation of the factors controlling the adsorption of protein antigens to anionic PLG microparticles. J. Pharm. Sci. 94 (2005) 2510-2519
20. Singh M., Chesko J., Kazzaz J., Ugozzoli M., Kan E., Srivastava I., and O'Hagan D.T. Adsorption of a novel recombinant glycoprotein from HIV (Env gp120dV2 SF162) to anionic PLG microparticles retains the structural integrity of the protein, whereas encapsulation in PLG microparticles does not. Pharm. Res. 21 (2004) 2148-2152
21. O'Hagan D., Singh M., Ugozzoli M., Wild C., Barnett S., Chen M., Schaefer M., Doe B., Otten G.R., and Ulmer J.B. Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines. J. Virol. 75 (2001) 9037-9043
22. Pal R., Yu Q., Wang S., Kalyanaraman V.S., Nair B.C., Hudacik L., Whitney S., Keen T., Hung C.L., Hocker L., Kennedy J.S., Markham P., and Lu S. Definitive toxicology and biodistribution study of a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 (HIV-1) vaccine in rabbits. Vaccine 24 (2006) 1225-1234
23. Cole K.S., Murphey-Corb M., Narayan O., Joag S.V., Shaw G.M., and Montelaro R.C. Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J. Virol. 72 (1998) 7852-7859
24. Selvarajah S., Puffer B., Pantophlet R., Law M., Doms R.W., and Burton D.R. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79 (2005) 12148-12163
25. Moore J.P., and Ho D.D. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J. Virol. 67 (1993) 863-875
26. Redhead K., Sesardic D., Yost S.E., Attwell A.M., Watkins J., Hoy C.S., Plumb J.E., and Corbel M.J. Interaction of Haemophilus influenzae type b conjugate vaccines with diphtheria-tetanus-pertussis vaccine in control tests. Vaccine 12 (1994) 1460-1466
27. Jeannin P., Renno T., Goetsch L., Miconnet I., Aubry J.P., Delneste Y., Herbault N., Baussant T., Magistrelli G., Soulas C., Romero P., Cerottini J.C., and Bonnefoy J.Y. OmpA targets dendritic cells, induces their maturation and delivers antigen into the MHC class I presentation pathway. Nat. Immunol. 1 (2000) 502-509
28. Haicheur N., Benchetrit F., Amessou M., Leclerc C., Falguieres T., Fayolle C., Bismuth E., Fridman W.H., Johannes L., and Tartour E. The B subunit of Shiga toxin coupled to full-size antigenic protein elicits humoral and cell-mediated immune responses associated with a Th1-dominant polarization. Int. Immunol. 15 (2003) 1161-1171
29. Kempf M., Mandal B., Jilek S., Thiele L., Voros J., Textor M., Merkle H.P., and Walter E. Improved stimulation of human dendritic cells by receptor engagement with surface-modified microparticles. J. Drug Target. 11 (2003) 11-18
30. Kazzaz J., Singh M., Ugozzoli M., Chesko J., Soenawan E., and O'Hagan D.T. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J. Control. Release 110 (2006) 566-573